Advances in Vaccines.
Advances in Vaccines. Adv Biochem Eng Biotechnol. 2019 Aug 25;: Authors: Mao HH, Chao S Abstract Vaccines represent one of the most important advances in science and medicine, helping people around the world in preventing the spread of infectious diseases. However, there are still gaps in vaccination programs in many countries. Out of 11.2 million children born in EU region, more than 500,000 infants did not receive the complete three-dose series of diphtheria, pertussis, and tetanus vaccine before the first birthday. Data shows that there were more than 30,000 measles cases in the European region in recent years, and measles cases are rising in the USA. There are about 20 million children in the world still not getting adequate coverage of basic vaccines. Emerging infectious diseases such as malaria, Ebola virus disease, and Zika virus disease also threaten public health around the world. This chapter provides an overview of recent advances in vaccine development and technologies, manufacturing, characterization of various vaccines, challenges, and strategies in vaccine clinical development. It also provides an overview of recently approved major vaccines for human use. PMID: 31446443 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: Journal of Genetics and GenomicsAuthor(s): Chengqi Wang, Justin Gibbons, Swamy R. Adapa, Jenna Oberstaller, Xiangyun Liao, Min Zhang, John H. Adams, Rays H.Y. Jiang
Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government ’s response to the pandemic.
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.(Image credit: Reinhard Dirscherl/ullstein bild via Getty Images)
Authors: Abdeta D, Kebede N, Giday M, Terefe G, Abay SM Abstract Microbial resistance to the few conventional antitrypanosomal drugs, increasing resistance of vectors to insecticides, lack of effective vaccines, and adverse effects of the existing antitrypanosomal drugs justify the urgent need for effective, tolerable, and affordable drugs. We assessed antitrypanosomal effects of the hydromethanolic extract of Echinops kebericho Mesfin roots against Trypanosoma congolense field isolate using in vitro and in vivo techniques. Parasite load, packed cell volume (PCV), body weight, and rectal temperature in Swiss albino...
Conclusion: This study demonstrates that the crude extract of A. hispidum DC, one of the plants used traditionally to treat malaria, inhibits the growth of P. falciparum in vitro and could be a potential source of antimalarial drug. The report has highlighted genotoxic and cytotoxic effects of the selected plant extracts on human leukocytes as well. PMID: 33029160 [PubMed]
Phoenix Children ’s Hospital held its fourth annual flu POD (point of distribution) this week, with this year's 13-hour blitz holding a special significance amid the global Covid-19 pandemic. On Oct. 7, nurses began vaccinating employees at 6 a.m. and concluded the one-day event at 7 p.m., vaccinating nearly 5,00 0 people. It’s preparation for another potential mass vaccination event: distribution of a safe and effective vaccine for Covid-19. Click through the photo gallery above to see scenes…
In this study, we modeled an alternative strategy to amplify tumor antigen-specific TCR transgenic CD8+ T cells through limited application of a long-acting IL-2 fusion protein, mIL-2/mCD25, which selectively targets the high-affinity IL-2R. Here, mice were vaccinated with a tumor antigen and high-dose mIL-2/mCD25 was applied to coincide with the induction of the high affinity IL-2R on tumor-specific T cells. A single high dose of mIL-2/mCD25, but not an equivalent amount of IL-2, amplified the frequency and function of tumor-reactive CD8+ T effector (Teff) and memory cells. These mIL-2/mCD25-dependent effects relied on di...
According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.
DiscussionThe results of this realist review will be written up according to RAMESES guidelines and disseminated through a stakeholder workshop in Malawi, through conference presentations and peer-reviewed publications. It is intended to improve the understanding of the potential and limits of working through Care Groups globally and among relevant Malawi Ministry of Health staff and the donor and NGO community, both internationally and within Malawi. This systematic review protocol has been submitted for registration on the PROSPERO database (receipt number: 170261).
ConclusionsPatients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24 weeks postvaccination.
More News: Biotechnology | Child Development | Children | Diphtheria | Ebola | Ebola Vaccine | Infectious Diseases | International Medicine & Public Health | Malaria | Malaria Vaccine | Measles | Measles Vaccine | Science | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine | Zika Virus